KATHRYN VOIGHT: Open Payments
NPI 1902477870 · MESA, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,810 in 110 payments from 24 companies in 2025. Trend: 2023 $1,095 · 2024 $1,654 · 2025 $2,810
Food & beverage: $2,616Education: $194
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $456 |
| Regeneron Healthcare Solutions, Inc. | 14 | $333 |
| GlaxoSmithKline, LLC. | 19 | $329 |
| GENZYME CORPORATION | 12 | $205 |
| Verona Pharma, Inc. | 8 | $196 |
| Axsome Therapeutics, Inc. | 6 | $167 |
| Grifols USA, LLC | 5 | $131 |
| Novo Nordisk Inc | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $122 |
| Actelion Pharmaceuticals US, Inc. | 4 | $120 |
Products named: DUPIXENT, FASENRA, NUCALA, Ohtuvayre, Sunosi, Prolastin-C Liquid, GLASSIA, BREZTRI.
Industry payments across AZ — which companies pay providers there.
